Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.
PAPERS | February 4-10, 2023 | |
Source: Cephalalgia 2023 Feb; 43(2). doi: 10.1177/03331024221141686Authors: Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L’Italien G, Morris BA, Coric V, Goadsby PJ
This post-hoc analysis from three phase 3 treatment trials of rimegepant 75 mg – an oral small molecule calcitonin gene-related peptide receptor antagonist for acute and preventive treatment of migraine – assessed efficacy in adults with migraine based on triptan treatment experience.
Pubmed ID: https://pubmed.ncbi.nlm.nih.gov/36739511/